Argenx (ARGX) announced that the FDA has accepted for priority review a supplemental biologics license application, or sBLA, for Vyvgart for the treatment of adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis. The application has been granted a Prescription Drug User Fee Act target action date of May 10.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx: Sustained Growth and Strategic Pipeline Upside Underpin Buy Rating
- Argenx: Sustained Vyvgart Momentum and Expanding FcRn Pipeline Underpin Buy Rating and Attractive Risk‑Reward
- argenx Posts 90% Sales Surge and Maps Pivotal 2026 Pipeline, Leadership Transition
- Argenx Advances Combo Strategy in Myasthenia Gravis With New ADAPT Forward Study
- ADAPT Forward: How Argenx’s New Myasthenia Gravis Study Could Shape Its Growth Story